期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

胃肠间质瘤的分子靶向药物治疗

下载PDF
导出
摘要 胃肠间质瘤（gastrointestinal stromal tumors,GIST）是胃肠道中一种特殊的恶性间质肿瘤,由突变的c-kit或血小板源性生长因子受体（PDGFRA）基因驱动,免疫组化CD117表达阳性,可以发生在整个胃肠道以及网膜和肠系膜上,占胃肠道肿瘤的2%左右[1]。手术完整切除仍然是根治胃肠间质瘤的惟一方法,但尽管经过根治性手术切除,
作者 张永强 李健
机构地区 北京大学肿瘤医院
出处 《基层医学论坛》 2013年第22期2961-2963,共3页 The Medical Forum
关键词 胃肠间质瘤 分子靶向药物治疗 血小板源性生长因子受体 根治性手术切除 恶性间质肿瘤 C-KIT CD117 免疫组化
分类号 R735 [医药卫生—肿瘤]
  • 相关文献

参考文献23

  • 1Fletcher CD, Bemaan JJ, Corless CC, et al.Diagnosis of gastrointestinal tumors: a consensus approach[J].Hum Pathol, 33 : 459 465,2002.
  • 2De Matteo RP,Lewis JJ,Leung D,et al.Two hundred gastrointestinal stromal tumors:recurrence pattern and prognostic factors for survival[J]. Ann Surg, 2000,231 : 51-58.
  • 3Edmonson JH,Marks RS,Buckner JC,et al.Contrast of response to dacarbazine, mitomycin, doxorubicin, and eisplatin (DMAP)plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas [J]. Cancer [nvet_ 2002_ 20- 60i-61.
  • 4Demetri GD,von Mehren M,Blanke CD,et al.Efficacy and safety of Imatinib Mesylate in advanced gastrointestinal stromal tumors[J].N Engl J Med, 2002,347: 472-480.
  • 5Cassier PA, Blesius AA, Perol D, et al.Neoadjuvant imatinib in patientswith locally advanced GIST in the prospective BFR14 trial.2009 ASCO Annual Meeting[J].J Clin Oncol, 2009,27 : 10551.
  • 6The NCCN Soft Tissue Sarcoma clinical practice guidelines in oncology (version 1.20t 1 ).
  • 7Casali PG, Jost L, Reichardt P, et al.Gastrointestinal stromal turnouts: ESMO Clinical Recommendations for diagnosis,treatment and follow-up[J].Ann Oncol, 2009,20: 64-67.
  • 8中国胃肠间质瘤诊断治疗专家共识(2011年版)[J].临床肿瘤学杂志,2011,16(9):836-844. 被引量：104
  • 9Blanke CD, Demetri GD, Mehren M yon, et al.Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT [J].J of Clin Oncol,2008,26 (4): 620-625.
  • 10Zalcberg JR, Verweij J, Casali PG, et al.EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, Australasian Gastrointestinal Trials Group. Outcome of patients with advanced gastrointestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg [J].Eur J Cancer,2005,41: 1751-1757.

二级参考文献66

  • 1贺慧颖,方伟岗,钟镐镐,李燕,郑杰,杜娟,衡万杰,吴秉铨.165例胃肠道间质瘤中c-kit和PDGFRA基因突变的检测和临床诊断意义[J].中华病理学杂志,2006,35(5):262-266. 被引量：73
  • 2Li J,Gong FJ,Shen L,et al.Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumour[J].Euro J Sur Oncol,2011,37(4):319-324.
  • 3Corless CL,Ballman KV,Antonescu C,et al.Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST):Results of the intergroup phase Ⅲ trial ACOSOG Z9001[J].J Clin Oncol,2010,28 (15 Suppl):a10006.
  • 4Joensuu H,Eriksson M,Hartmann J,et al.Twelve vs 36 months of adjuvant imatinib as treatment of operable GIST with a high risk of recurrence:final results of a randomized trial (SSGXⅧ/AIO)[J].J Clin Oncol,2011,29(Suppl):aLBAI.
  • 5DeMatteo RP,Owzar K,Antonescu CR,et al.Efficacy of adjuvant imatinib mesylate following complete resection of localized,primary gastrointestinal stromal tumor (GIST) at high risk of recurrence:The U.S.Intergroup phase Ⅱ trial ACOSOG Z9000[C/OL].2011[2011-07-29].http://www.anco.org/ascov2/Meetings/Abstracts? &vmview = abst-detail-view&confID =53&abstractID = 10450.
  • 6Demetri GD,von Meherm M,Blanke CD,et al.Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors[J].N Engl J Med,2002,347(7):472-480.
  • 7Zalcberg JR,Verweij J,Casali PG,et al.Outcome of patients with advanced gastrointestinal stromal tumours croasing over to a daily imatinib dose of 800 mg after progression on 400 mg[J].Eur J Cancer,2005,41 (12):1751-1757.
  • 8Rios M,Lecesne A,Bui B,et al.Interruption of imatinib (IM)in GIST patients with advanced disease after one year of treatment:Updated results of the prospective French Sarcoma Group randomized phase Ⅲ trial on long term survival[J].J Clin Oncol,2007,25(18 Suppl):10016.
  • 9Raut CP,Posner M,Dessi J,et al,Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors[J].J Clin Oncol,2006,24(15):2325-2331.
  • 10DeMatteo RP,Maki RG,Singer S,et al.Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor[J].Ann Surg,2007,245 (3):347-352.

共引文献134

基层医学论坛
2013年 第22期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部